Ihuman Inc Stock EBITDA
| IH Stock | USD 1.71 0.02 1.16% |
Ihuman Inc fundamentals help investors to digest information that contributes to Ihuman's financial success or failures. It also enables traders to predict the movement of Ihuman Stock. The fundamental analysis module provides a way to measure Ihuman's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Ihuman stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | 171.6 M | 180.2 M |
Ihuman | EBITDA |
Ihuman Inc Company EBITDA Analysis
Ihuman's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Ihuman EBITDA | 171.58 M |
Most of Ihuman's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ihuman Inc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Ihuman EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for Ihuman is extremely important. It helps to project a fair market value of Ihuman Stock properly, considering its historical fundamentals such as EBITDA. Since Ihuman's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Ihuman's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Ihuman's interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
Ihuman Ebitda
Ebitda |
|
According to the company disclosure, Ihuman Inc reported earnings before interest,tax, depreciation and amortization of 171.58 M. This is 88.67% lower than that of the Hotels, Restaurants & Leisure sector and 21.16% higher than that of the Consumer Discretionary industry. The ebitda for all United States stocks is 95.6% higher than that of the company.
Ihuman EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ihuman's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Ihuman could also be used in its relative valuation, which is a method of valuing Ihuman by comparing valuation metrics of similar companies.Ihuman is currently under evaluation in ebitda category among its peers.
Ihuman Current Valuation Drivers
We derive many important indicators used in calculating different scores of Ihuman from analyzing Ihuman's financial statements. These drivers represent accounts that assess Ihuman's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Ihuman's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 5.0B | 5.4B | 941.4M | 955.9M | 1.2B | 1.2B | |
| Enterprise Value | 4.9B | 4.5B | 120.3M | (85.0M) | 7.9M | 7.5M |
Ihuman Institutional Holders
Institutional Holdings refers to the ownership stake in Ihuman that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Ihuman's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Ihuman's value.| Shares | Arisaig Partners (asia) Pte Ltd | 2024-06-30 | 1.2 M | Citadel Advisors Llc | 2024-09-30 | 38.4 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 19.9 K | Rhumbline Advisers | 2024-09-30 | 11.4 K | Two Sigma Securities, Llc | 2024-09-30 | 11.2 K | Crédit Agricole S.a. | 2024-09-30 | 10 K | Ubs Group Ag | 2024-09-30 | 4.5 K | State Street Corp | 2024-09-30 | 0.0 | Susquehanna International Group, Llp | 2024-06-30 | 0.0 | Qube Research & Technologies | 2024-09-30 | 0.0 | Xtx Topco Ltd | 2024-09-30 | 0.0 |
Ihuman Fundamentals
| Return On Equity | 0.15 | ||||
| Return On Asset | 0.0456 | ||||
| Profit Margin | 0.14 % | ||||
| Operating Margin | 0.09 % | ||||
| Current Valuation | (67.16 M) | ||||
| Shares Outstanding | 23.57 M | ||||
| Shares Owned By Institutions | 0.61 % | ||||
| Number Of Shares Shorted | 6.13 K | ||||
| Price To Earning | 7.83 X | ||||
| Price To Book | 0.70 X | ||||
| Price To Sales | 0.09 X | ||||
| Revenue | 1.02 B | ||||
| Gross Profit | 660.62 M | ||||
| EBITDA | 171.58 M | ||||
| Net Income | 180.91 M | ||||
| Cash And Equivalents | 1.05 B | ||||
| Cash Per Share | 16.08 X | ||||
| Total Debt | 3.86 M | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 2.27 X | ||||
| Book Value Per Share | 17.36 X | ||||
| Cash Flow From Operations | 172.12 M | ||||
| Short Ratio | 0.29 X | ||||
| Earnings Per Share | (0.16) X | ||||
| Target Price | 3.86 | ||||
| Number Of Employees | 783 | ||||
| Beta | 0.47 | ||||
| Market Capitalization | 90.08 M | ||||
| Total Asset | 1.45 B | ||||
| Retained Earnings | (140.46 M) | ||||
| Working Capital | 891.68 M | ||||
| Annual Yield | 0.06 % | ||||
| Net Asset | 1.45 B |
About Ihuman Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ihuman Inc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ihuman using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ihuman Inc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Ihuman Piotroski F Score and Ihuman Altman Z Score analysis. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Hotels, Restaurants & Leisure space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ihuman. If investors know Ihuman will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ihuman listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.40) | Earnings Share (0.16) | Revenue Per Share 18.263 | Quarterly Revenue Growth (0.11) | Return On Assets 0.0456 |
The market value of Ihuman Inc is measured differently than its book value, which is the value of Ihuman that is recorded on the company's balance sheet. Investors also form their own opinion of Ihuman's value that differs from its market value or its book value, called intrinsic value, which is Ihuman's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ihuman's market value can be influenced by many factors that don't directly affect Ihuman's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ihuman's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ihuman is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ihuman's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.